<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654431</url>
  </required_header>
  <id_info>
    <org_study_id>ASI-ER/PR-IHC</org_study_id>
    <nct_id>NCT02654431</nct_id>
  </id_info>
  <brief_title>Identification and Semi -Quantification of ER/PR Proteins Expression</brief_title>
  <official_title>Identification and Semi -Quantification of ER/PR Proteins Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Spectral Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Spectral Imaging Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is the identification and quantification of proteins expression
      level in breast cancer tissues.

      The imaging system is intended for diagnostic use as an aid to the pathologist in the
      detection, counting and classifying ER/PR IHC stained samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The anti ER/PR Kit is a semi-quantitative immunohistochemical (IHC) assay to identify the
      progesterone (PR) and estrogen (ER) expressions in formalin-fixed, paraffin-embedded human
      breast cancer tissue specimens. Results from the ER/PR test is indicated as an aid in the
      assessment of the hormones status of breast cancer patients. While the ER/PR kit provides the
      antibodies that offer direct visualization and semi-quantification of the protein expression
      through a brightfield microscope, the GenASIs GoPath system is designed to complement the
      routine workflow of the pathologist in the review of immunohistochemically stained histologic
      slides.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IVD study of ER/PR IHC samples: Accuracy of analysis</measure>
    <time_frame>1 Day</time_frame>
    <description>Comparison tests (accuracy) between manual and automatic analysis of antibody expressions. The results from the automatic counting from the clinical studies will be compared to the manual counting analysis.
Accuracy of the study will be declared &quot;Success&quot; if Positive, Negative and Overall agreement with manual count of the ER &amp; PR antibody at least 90%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IVD study of ER/PR IHC samples: Repeatability &amp; Reproducibility of analysis</measure>
    <time_frame>1 Day</time_frame>
    <description>Repeatability &amp; Reproducibility tests of system analysis of antibody expressions. R&amp;R acceptance criteria of ER/PR are related to the average agreement for between runs, between days and between systems R&amp;R part of the study will be declared &quot;Success&quot; if Positive and Negative average agreement will be at least 85%.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">350</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer patients</arm_group_label>
    <description>Breast cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>women with breast cancer</arm_group_label>
    <description>women with breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer patients</arm_group_label>
    <description>Cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast Cancer patient</intervention_name>
    <description>Samples</description>
    <arm_group_label>Breast Cancer patients</arm_group_label>
    <arm_group_label>women with breast cancer</arm_group_label>
    <arm_group_label>Cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cancer patients</intervention_name>
    <description>Samples</description>
    <arm_group_label>Breast Cancer patients</arm_group_label>
    <arm_group_label>women with breast cancer</arm_group_label>
    <arm_group_label>Cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women having breast cancer

        Exclusion Criteria:

          -  others
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Dobin</last_name>
    <role>Study Chair</role>
    <affiliation>Section Chief, Cytogenetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scott &amp; White Hospital,,</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunohistochemical (IHC)</keyword>
  <keyword>ER/PR</keyword>
  <keyword>Breast cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

